59 related articles for article (PubMed ID: 24330848)
1. Anti-inflammatory effect of full-length adiponectin and proinflammatory effect of globular adiponectin in esophageal adenocarcinoma cells.
Zhang R; Wu J; Liu D; Shan H; Zhang J
Oncol Res; 2013; 21(1):15-21. PubMed ID: 24330848
[TBL] [Abstract][Full Text] [Related]
2. Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion.
Trevellin E; Scarpa M; Carraro A; Lunardi F; Kotsafti A; Porzionato A; Saadeh L; Cagol M; Alfieri R; Tedeschi U; Calabrese F; Castoro C; Vettor R
Oncotarget; 2015 May; 6(13):11203-15. PubMed ID: 25857300
[TBL] [Abstract][Full Text] [Related]
3. Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1.
Wang J; Cheng Y; Yin X; Wu J; Luo Y; Wu J; Di J; Liu D; Huang Y; Zhang R; Zhang J
Mol Cell Biochem; 2017 Jul; 431(1-2):103-112. PubMed ID: 28285359
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma.
Alexandre L; Long E; Beales IL
World J Gastrointest Pathophysiol; 2014 Nov; 5(4):534-49. PubMed ID: 25400997
[TBL] [Abstract][Full Text] [Related]
5. Leptin and adiponectin receptor expression in oesophageal cancer.
Howard JM; Cathcart MC; Healy L; Beddy P; Muldoon C; Pidgeon GP; Reynolds JV
Br J Surg; 2014 May; 101(6):643-52. PubMed ID: 24664553
[TBL] [Abstract][Full Text] [Related]
6. Role of Obesity in the Pathogenesis and Progression of Barrett's Esophagus.
Chandar AK; Iyer PG
Gastroenterol Clin North Am; 2015 Jun; 44(2):249-64. PubMed ID: 26021193
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease.
Almers LM; Graham JE; Havel PJ; Corley DA
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2256-64.e1-3. PubMed ID: 25632808
[TBL] [Abstract][Full Text] [Related]
8. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
9. Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer.
Di Caro S; Cheung WH; Fini L; Keane MG; Theis B; Haidry R; Di Renzo L; De Lorenzo A; Lovat L; Batterham RL; Banks M
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):251-60. PubMed ID: 26671515
[TBL] [Abstract][Full Text] [Related]
10. A high-fat diet is associated with altered adipokine production and a more aggressive esophageal adenocarcinoma phenotype in vivo.
Fowler AJ; Richer AL; Bremner RM; Inge LJ
J Thorac Cardiovasc Surg; 2015 Apr; 149(4):1185-91. PubMed ID: 25595377
[TBL] [Abstract][Full Text] [Related]
11. The role of obesity in oesophageal cancer development.
Long E; Beales IL
Therap Adv Gastroenterol; 2014 Nov; 7(6):247-68. PubMed ID: 25364384
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients.
Diakowska D; Markocka-Mączka K; Szelachowski P; Grabowski K
Dis Markers; 2014; 2014():619649. PubMed ID: 25049439
[TBL] [Abstract][Full Text] [Related]
13. Interaction between Esophageal Squamous Cell Carcinoma and Adipose Tissue in Vitro.
Nakayama A; Aoki S; Uchihashi K; Nishijima-Matsunobu A; Yamamoto M; Kakihara N; Iwakiri R; Fujimoto K; Toda S
Am J Pathol; 2016 May; 186(5):1180-94. PubMed ID: 26952643
[TBL] [Abstract][Full Text] [Related]
14. Esophageal adenocarcinoma microenvironment: Peritumoral adipose tissue effects associated with chemoresistance.
Carraro A; Trevellin E; Fassan M; Kotsafti A; Lunardi F; Porzionato A; Dall'Olmo L; Cagol M; Alfieri R; Macchi V; Tedeschi U; Calabrese F; Rugge M; Castoro C; Vettor R; Scarpa M
Cancer Sci; 2017 Dec; 108(12):2393-2404. PubMed ID: 28985034
[TBL] [Abstract][Full Text] [Related]
15. Associations of Serum Adiponectin and Leptin With Barrett's Esophagus.
Greer KB; Falk GW; Bednarchik B; Li L; Chak A
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2265-72. PubMed ID: 25737442
[TBL] [Abstract][Full Text] [Related]
16. The feasibility of an exercise intervention in males at risk of oesophageal adenocarcinoma: a randomized controlled trial.
Winzer BM; Paratz JD; Whitehead JP; Whiteman DC; Reeves MM
PLoS One; 2015; 10(2):e0117922. PubMed ID: 25706622
[TBL] [Abstract][Full Text] [Related]
17. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
18. Inhibition effect of glycyrrhizin in lipopolysaccharide-induced high-mobility group box 1 releasing and expression from RAW264.7 cells.
Wu CX; He LX; Guo H; Tian XX; Liu Q; Sun H
Shock; 2015 Apr; 43(4):412-21. PubMed ID: 25526376
[TBL] [Abstract][Full Text] [Related]
19. Influence of metabolic syndrome on upper gastrointestinal disease.
Sogabe M; Okahisa T; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
Clin J Gastroenterol; 2016 Aug; 9(4):191-202. PubMed ID: 27372302
[TBL] [Abstract][Full Text] [Related]
20. Ghrelin and Leptin Have a Complex Relationship with Risk of Barrett's Esophagus.
Thomas SJ; Almers L; Schneider J; Graham JE; Havel PJ; Corley DA
Dig Dis Sci; 2016 Jan; 61(1):70-9. PubMed ID: 26396004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
